（来源：千龙网） 出台专项支持政策、搭建关键共性服务平台、营造产业生态……以微元合成为代表，昌平区的合成生物 制造产业规模正在加速扩展。截至目前，落户昌平的合成生物制造企业数量为146家。在生物基新材 料、胶原蛋白、生物育种、气体发酵等合成生物制造细分领域，均有企业持续深耕。 目前，昌平合成生物制造产业已经进入集群化发展新阶段。昌平区相关负责人透露了新年新目标：2026 年，昌平区力争新落地10个合成生物制造标志性项目，实现合成生物制造产业收入突破100亿元。接下 来，昌平区将从区域领先迈向全国引领，逐渐形成重要影响力和号召力，打造合成生物制造创新策源地 和产业引领区。 春节假期刚过，在未来科学城合成生物制造产业创新孵化区及转化加速区内，一批微生物"工人"已经开 工，不知疲倦地高效产出阿洛酮糖、饲料蛋白等"生物造"产品。与2025年同期相比，在北京昌平区落户 的合成生物制造企业数量增长近七成，产业规模持续壮大，集聚效应日益凸显。 从实验室里的毫克级样品，到工业生产线上的吨级产品，园区内，微元合成生物技术（北京）有限公司 已成功实现甘露醇、阿洛酮糖、木糖醇等产品的商业化落地，聚焦人类营养、动物营养、日化原料、药 ...

走进实验室，整齐排列的一个个生物反应器，就是一座座"无声工厂"，肉眼不可见的微生物作为"新型 工人"，一呼一吸之间就能生产各类合成生物产品，堪称"生物造万物"。刘波介绍，最近，"新型工 人"的研发也在持续进行，公司菌种库内保存的微生物样本已达十余万种，随着研发的推进，这个数字 仍在不断增长。 出台专项支持政策、搭建关键共性服务平台、营造产业生态……以微元合成为代表，昌平区的合成生物 制造产业规模正在加速扩展。截至目前，落户昌平的合成生物制造企业数量为146家。在生物基新材 料、胶原蛋白、生物育种、气体发酵等合成生物制造细分领域，均有企业持续深耕。 目前，昌平合成生物制造产业已经进入集群化发展新阶段。昌平区相关负责人透露了新年新目标：2026 年，昌平区力争新落地10个合成生物制造标志性项目，实现合成生物制造产业收入突破100亿元。接下 来，昌平区将从区域领先迈向全国引领，逐渐形成重要影响力和号召力，打造合成生物制造创新策源地 和产业引领区。 本报讯（记者 刘苏雅）春节假期刚过，在未来科学城合成生物制造产业创新孵化区及转化加速区内， 一批微生物"工人"已经开工，不知疲倦地高效产出阿洛酮糖、饲料蛋白等"生物造"产 ...

2月26日，华康股份涨5.21%，截至发稿，报17.16元/股，成交8109.59万元，换手率1.62%，总市值52.00 亿元。 资料显示，浙江华康药业股份有限公司位于浙江省开化县华埠镇华工路18号，成立日期2001年7月10 日，上市日期2021年2月9日，公司主营业务涉及木糖醇、山梨糖醇、麦芽糖醇、果葡糖浆等多种功能性 糖醇、淀粉糖产品的研发、生产、销售。主营业务收入构成为：晶体糖醇产品54.36%，液体糖、醇及 其他产品32.46%，其他13.18%。 华夏卓越成长混合A（024928）成立日期2025年8月12日，最新规模8.98亿。今年以来收益15.06%，同 类排名859/8887；成立以来收益33.45%。 华夏卓越成长混合A（024928）基金经理为钟帅。 截至发稿，钟帅累计任职时间5年215天，现任基金资产总规模119.14亿元，任职期间最佳基金回报 222.31%， 任职期间最差基金回报13.2%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本 文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@ ...

过去几年，芬兰人靠着树皮发家，日本人凭着技术定价，而中国河南安阳一出手，就把全局翻了盘。谁 都没想到，一个靠玉米芯发电、做锅炉料的地方，能用这堆"废料"搅了全球代糖市场的局——几千块一 吨卖出的木糖醇，如今直接干到白菜价，简直是"穷人靠抠，富人靠价，安阳靠脑袋"的真实写照。这不 是工业小聪明，这是赤裸裸的产业降维打击。 这几年自主研发投入加大，几家当地龙头企业合作联动科研团队，把从玉米芯中提取木糖醇的整套流程 做到了极致。比如在水解与脱色这两个最费能耗的环节优化出工艺稳定模式，同时引入清洁能源原料 链，一系列改造之后，最终把成本狠狠砍了一刀。 2025年的数据让人侧目，安阳本地数十家企业单年产能突破10万吨，最低出厂价格跑到了2.1万元/吨以 下。这不是降价促销，是技术压倒性优势下的正常出价。而这还只是起点，背后还有禹城、衡水等一批 新兴区域在跟进。 要说木糖醇这东西，最早确实不是中国的"配方"。发明它的，是北欧人，种得不是甜菜，是财富密码。 特别是芬兰，地广林多，白桦树比人还容易聚集人口。几十年前，丹尼斯克这样的传统巨头就把木糖醇 商业化，从白桦树皮里提取出来，既能防蛀牙，还不升血糖，迅速成为高端食品工业里 ...

Core Insights - Shandong Futen Pharmaceutical Co., Ltd. launched four core products at a strategic release event, marking a significant step towards consumer branding in the functional sugar sector [1] - The new products focus on health, convenience, and scenario-based usage, aligning with global market trends in low-calorie and low-glycemic index options [1][2] - The company aims to leverage its expertise in xylitol production to transition from B2B to B2C markets, emphasizing the need for innovation and new applications [2] Product Development - The four new products include sugar-free coffee candy, tea tablets, small-packaged xylitol, and L-arabinose, developed to meet health management needs [1] - The xylitol series is positioned to benefit from a global compound annual growth rate of approximately 5%, while the L-arabinose series targets an annual growth rate of about 8% in the sugar reduction market [1] - Futen Pharmaceutical has established a comprehensive R&D system, investing 3% of annual revenue into research and collaborating with top academic institutions [2] Market Position and Strategy - As a leading domestic producer of xylitol, Futen Pharmaceutical has built a green circular economy supply chain, exporting products to over 50 countries [1] - The company has achieved a 30% market share in domestic xylitol using its proprietary clean production process, which enhances product purity to over 99.9% and reduces energy consumption by 15% [2] - The transition to consumer markets is supported by a dedicated online sales team and expansion into offline retail channels [2] Future Outlook - The domestic market for sugar-free and low-GI foods is projected to grow at an annual rate of 15%, presenting significant opportunities for Futen Pharmaceutical [3] - The company's transformation is expected to not only create new growth pathways but also accelerate the overall upgrade of the functional sugar industry in Yucheng [3]

Core Viewpoint - The timely provision of a 1 million yuan loan to a local enterprise engaged in the processing of corn cobs highlights the importance of financial support for small and micro enterprises, especially in challenging conditions like heavy snowfall [1][2] Group 1: Company Operations - The enterprise, led by Mr. Dong, specializes in the acquisition and deep processing of corn cobs, converting agricultural waste into high-value products such as furfural and xylitol [1] - The utilization of corn cobs not only enhances the income of local farmers but also creates job opportunities, contributing to a green and prosperous industry [1] Group 2: Financial Support and Impact - The company faced a liquidity challenge due to significant investments in equipment upgrades and raw material storage, prompting the need for a 1 million yuan working capital loan [1] - The bank's commitment to conducting on-site investigations and promptly disbursing the loan demonstrates its trust in local industries and its dedication to supporting small businesses during tough times [2] - With the loan secured, the company can stabilize its inventory and expand its procurement scale, ensuring full operational capacity throughout the year [2]

Core Viewpoint - The article emphasizes the importance of understanding pet dietary restrictions, highlighting eight major food items that are toxic to pets, which can lead to severe health issues or even death if consumed [10][74]. Group 1: Pet Food Taboos - Chocolate is highly toxic to pets, particularly dogs and cats, due to their inability to metabolize theobromine and caffeine, leading to symptoms like vomiting, diarrhea, and potentially fatal heart failure [12][16]. - Grapes and raisins can cause acute kidney failure in pets, with no established safe consumption level, making them extremely dangerous [19][23]. - Onions, garlic, and related products contain compounds that can destroy red blood cells in pets, leading to hemolytic anemia, with symptoms that may appear days after ingestion [26][30]. - Xylitol, an artificial sweetener found in sugar-free products, can cause a rapid drop in blood sugar and liver damage in pets, with symptoms appearing within 15-30 minutes of consumption [33][39]. - Alcohol is harmful to pets, causing liver damage and neurological issues, with even small amounts leading to severe health consequences [42][46]. - High-salt and high-fat foods, such as pickled products and fried foods, can lead to kidney strain, obesity, and pancreatitis in pets [48][50]. - Sharp bones, particularly from cooked poultry and fish, can splinter and cause serious internal injuries to pets [54][62]. - Dairy products, including milk, can cause digestive issues in pets due to their inability to process lactose after weaning, leading to gastrointestinal distress [66][70]. Group 2: Dietary Guidelines - The article advises pet owners to prioritize specialized pet food that meets the specific needs of their pets, rather than human food, to avoid dietary mistakes that could harm their pets [74][76]. - In case of accidental ingestion of toxic foods, it is crucial to seek immediate veterinary assistance while providing details about the consumed items [77].

Core Viewpoint - Huakang Co., Ltd. experienced a decline of 1.06% on December 30, with a stock price of 14.92 yuan per share and a total market capitalization of 4.522 billion yuan [1] Company Overview - Zhejiang Huakang Pharmaceutical Co., Ltd. was established on July 10, 2001, and went public on February 9, 2021. The company specializes in the research, production, and sales of various functional sugar alcohols and starch sugar products, including xylitol, sorbitol, maltitol, and fructose syrup [1] - The revenue composition of the company is as follows: crystalline sugar alcohol products account for 54.36%, liquid sugars and alcohols for 32.46%, and other products for 13.18% [1] Shareholder Information - Huaxia Fund has a presence among the top ten circulating shareholders of Huakang Co., Ltd. The Huaxia Excellent Growth Mixed A Fund (024928) entered the top ten shareholders in the third quarter, holding 4.1533 million shares, which represents 1.39% of the circulating shares [2] - The estimated floating loss for the fund today is approximately 664,500 yuan [2][5] Fund Performance - The Huaxia Excellent Growth Mixed A Fund (024928) was established on August 12, 2025, with a current scale of 956 million yuan and a cumulative return of 16.17% since inception [3] - The fund manager, Zhong Shuai, has been in position for 5 years and 157 days, managing assets totaling 13.26 billion yuan. The best fund return during his tenure is 184.12%, while the worst return is -0.15% [4]

Core Viewpoint - Huakang Co., Ltd. has decided to terminate the planned acquisition of 100% equity in Yuxin Sugar Alcohol due to significant changes in the market environment since the initial planning phase, despite the transaction being in progress for over a year [2][4]. Group 1: Transaction Details - The company intended to acquire Yuxin Sugar Alcohol for a total price of 1.098 billion yuan through a combination of issuing shares and cash payments [2]. - The assessment value of Yuxin Sugar Alcohol's 100% equity as of December 31, 2024, was 1.101 billion yuan, reflecting an increase of 556 million yuan and an appreciation rate of 102.01% [2][3]. Group 2: Company Performance - Huakang Co., Ltd. has faced a situation of increasing revenue without corresponding profit growth, with a revenue increase of 0.93% to 2.808 billion yuan in 2024, while net profit decreased by 27.72% to 268 million yuan [4]. - In the first three quarters of 2025, the company reported a revenue of 2.959 billion yuan, a year-on-year increase of 40.52%, but net profit declined by 9.91% to 168 million yuan [4]. Group 3: Industry Context - The company and Yuxin Sugar Alcohol are recognized as leading firms in the production and technology of xylitol, with the acquisition aimed at enhancing market competitiveness and operational efficiency [4]. - The industry is currently facing challenges, including a major customer of Yuxin Sugar Alcohol experiencing a debt crisis, which may impact the market dynamics [4].

Core Viewpoint - Huakang Co., Ltd. has terminated its acquisition of Henan Yuxin Sugar Alcohol Co., Ltd. after a year of planning, citing significant changes in the market environment since the initial planning phase [1][3]. Group 1: Acquisition Details - The acquisition was initiated on October 26, 2024, with a transaction price of approximately 1.098 billion yuan, which would have made Yuxin Sugar Alcohol a wholly-owned subsidiary of Huakang [3]. - Yuxin Sugar Alcohol is recognized in the functional sugar alcohol industry, with high production technology and significant xylitol capacity, contributing to Huakang's competitive advantage in the domestic and international markets [3]. Group 2: Financial Performance - Huakang's revenue for 2024 was 2.808 billion yuan, a slight increase of 0.93% year-on-year, while the net profit attributable to shareholders decreased by 27.72% to 268 million yuan [4]. - In the first three quarters of 2025, the company achieved revenue of 2.959 billion yuan, a year-on-year increase of 40.52%, but the net profit attributable to shareholders fell by 9.91% to 168 million yuan [4]. Group 3: Future Growth Strategies - The company is focusing on the release and digestion of its own production capacity, particularly through the construction of a 2 million-ton corn deep processing health food ingredient project in Zhoushan, Zhejiang [5]. - The first phase of the project, with a capacity of 1 million tons, has been completed, and the company is gradually increasing production efficiency [5]. - To improve profitability, the company needs to focus on high-growth application scenarios, optimize its product matrix, and strengthen supply chain collaboration to reduce costs [5].